[Cardiac remodeling after myocardial infarction : Clinical practice update].
G Ertl1, S Brenner2, C E Angermann2
1Medizinische Klinik I und Deutsches Zentrum für Herzinsuffizienz, Universitätsklinikum und Universität Würzburg, Am Schwarzenberg 15, 97078, Würzburg, Deutschland. Ertl_G@ukw.de.
Herz
|January 21, 2017
Summary
Heart failure, a leading cause of death and hospitalization, involves cardiac remodeling. Early diagnosis and treatment of myocardial infarction, alongside standard therapies, are crucial for preserving heart function.
Area of Science:
- Cardiology
- Cardiovascular Medicine
- Pathophysiology
Background:
- Heart failure is a major cause of death and hospitalization, particularly in Germany.
- Therapeutic options have improved, especially for heart failure with reduced ejection fraction.
- Cardiac remodeling, involving cellular and molecular changes, precedes clinical heart failure symptoms.
Purpose of the Study:
- To summarize current understanding of heart failure pathophysiology and management.
- To highlight the importance of early diagnosis and treatment of myocardial infarction.
- To discuss standard pharmacotherapies and emerging treatments targeting infarct healing.
Main Methods:
- Review of existing literature on heart failure, cardiac remodeling, and myocardial infarction.
- Analysis of therapeutic strategies, including pharmacotherapy and reperfusion.
- Discussion of cellular and molecular processes involved in healing after myocardial infarction.
Main Results:
- Early reperfusion therapy effectively limits infarct size and preserves left ventricular function.
- Standard pharmacotherapy (ACE inhibitors, ARBs, beta-blockers) and mineralocorticoid receptor antagonists improve outcomes.
- Ongoing research focuses on novel compounds targeting infarct healing.
Conclusions:
- Effective management of heart failure requires a multi-faceted approach, including timely intervention for myocardial infarction.
- Current therapies significantly improve outcomes, but further advancements are needed.
- Targeting infarct healing processes holds promise for future heart failure treatments.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
9.2K
09:29An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
Published on: July 14, 2023
1.3K
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
564
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
564
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
593
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
593
01:30Cardiomyopathy II: Dilated Cardiomyopathy
689
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
689
01:28Acute Coronary Syndrome IV: Interprofessional Care
361
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
361
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
699
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
699
01:14Myocarditis III: Medical Management
282
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
282